No Picture
News

Biocept Announces Clinical Validation and Commercial Launch of its Target Selector(TM) Multi-Gene Liquid Biopsy Panel for Lung Cancer

Biocept now positioned as the only commercial liquid biopsy provider that offers single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis

SAN DIEGO, May 20, 2019 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading comm… […]

No Picture
News

Respivant Sciences Announces Dosing of First Patient in Phase 2b Trial of RVT-1601 for the Treatment of Persistent Cough Due to Idiopathic Pulmonary Fibrosis

RVT-1601 previously demonstrated a statistically significant and clinically meaningful reduction in IPF-related cough in a Phase 2a studyRespivant also launches new website – IPFCough.com – as educational resource for patients and to increase awareness… […]

No Picture
News

Wellspring Biosciences Announces Clearance of IND Application to Initiate Phase 1 Trial of KRAS G12C Mutant Inhibitor ARS-3248

SAN DIEGO, May 16, 2019 /PRNewswire/ — Wellspring Biosciences, Inc., a wholly owned subsidiary of Araxes Pharma, LLC, announced today that the U.S. Food and Drug Administration has cleared an investigational new drug (IND) application for ARS-3248,… […]

No Picture
News

Epic Sciences to Present New Data Identifying Multiple Cancer Biomarkers Associated with Treatment Response in Prostate and Bladder Cancer at ASCO 2019

SAN DIEGO, May 15, 2019 /PRNewswire/ — Epic Sciences, Inc. today announced its poster presentations for the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 through June 4 in Chicago, Illinois. The data … […]

No Picture
News

Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 to be Featured in Oral Presentation at Digestive Disease Week (DDW) 2019

Presentation to Highlight Positive Data Demonstrating Clinical and Biomarker Activity Suggesting Localized Target Engagement and Minimal Systemic Exposure Following Four Weeks of Treatment in Patients with Moderately-to-Severely Active Ulcerative Colit… […]

No Picture
News

Janssen Demonstrates Strong Commitment to Inflammatory Bowel Disease with Data from 25 Abstracts Presented at the 2019 Digestive Disease Week Annual Meeting

Phase 3 Data Evaluating STELARA® (ustekinumab) Efficacy and Safety in Patients with Moderate to Severe Ulcerative Colitis Featured in Two Oral Presentations

SAN DIEGO, May 14, 2019 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson &… […]

No Picture
News

Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019

— Oral plenary presentation to detail properties of oral, gut-restricted alpha-4-beta-7 integrin antagonist candidate PN-943 —

NEWARK, Calif., May 7, 2019 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Larry Matth… […]